2026 SPEAKERS
Paul Moore
Chief Scientific Officer, Zymeworks, USA
David Huang
Senior Director, Head of ADC Enabling Technologies, OBI Pharma, Taiwan
Bin Zou
Founder and CEO, Axcynsis Therapeutics, Singapore
Ben Ayers
Vice President, Antibody-Drug Conjugates, Hummingbird Bioscience, Singapore
Simon Shih-Hsien Chuang
CEO, Honeybear Biosciences, Taiwan
Doo Young Jung
CEO, Pinotbio Inc, South Korea
John Flygare
Head of ADC and Large Molecule Innovation Goup, Eli Lilly, USA
Veronica Diermayr
Director, Asset Lead, Experimental Drug Development Centre (EDDC), Singapore
Pini Tsukerman Ph.D
Co-Founder & CSO, Nectin Therapeutics Ltd, Israel
Abbas Sahili
CTO, Singzyme, Singapore
Anandayu Nurfachtiyani
GMP Lead Inspector, The Indonesian FDA (Badan POM), Indonesia
Aditya Pathak
Director, Oncology Medical Lead - MISP Cluster, Pfizer, Singapore
Dr. Nan Yu
Senior Director and ADC MedChem Group Head, Innovent Biologics, China
Haiqing Hua
SVP, Head of Drug Discovery, Duality Bio, China
Giorgio Salciarini
Head of Sales - Technical Business Development, BSP Pharmaceuticals, Italy
Mu Lin
Senior Director, Nona Biosciences, China
Ikuo Tsujimoto
Research Fellow – Process Engineering & CMC Development, Astellas Pharma, Japan
Inderjeet Singh
Director, EDDC, Singapore
Dr. Changshou Gao
CTO and Head of Biologics Research, Shanghai Allist Pharmaceuticals, China
Jun Hu
VP, Head of XDC CEC and Singapore Site Management, WuXi XDC, Singapore
Ee Xien Ng, Ph.D.
Technical Expert, APAC, BioReliance® Contract Testing Services, Advanced Solutions, Merck Lifescience, Singapore
Shantanu Laddha
Process Consultant, Sartorius Stedim India Pvt. Ltd., India
Chua Sook Wern
Operations and Strategy Consultant, Scientia Clinical Research, Australia
Brett Alderson
General Manager, BioCina, Australia
Crystal Wang
Oncology Therapeutic Area Medical Lead, Singapore, Malaysia, Brunei
